Aim To evaluate the effect of strontium ranelate in treatment of women with glucocorticoidinduced osteoporosis.
Methods There were examined 241 women with glucocorticoidinduced osteoporosis (average age 59,6±11,1 years, average height 161,3±6,4 cm, average weight 70,4±12,8 kg).
Evaluation of pain syndrome and level of physical activity was carried out with visual analogue scale (VAS). Examination was performed before onset of treatment and after a four, eight and twelve month treatment course. Strontium ranelate (Bivalos, “Servier”) was taken in a dose of one 2 g sachet as a suspension in water once a day and 1 tablet of Calcemin-advance (Calcium – 500 mg, Vit. D – 400 IU) 2 times a day during 12 months.
Results The patients had the risk factors of osteoporosis: 24% of patients had osteoporotic fractures in their anamnesis; 19% – hip fractures in mother or father of patients and 28% – smoking. We observed a reliable decrease of vertebral pain syndrome after four months of treatment by 14%, after eight months – 35%; after twelve months – 47% (d<0.00001) and increase of functional abilities of patients after four months of treatment by 47%, after eight months – 86%; after twelve months – 100% (d<0.00001).
Conclusions It has been demonstrated that strontium ranelate treatment significantly decreases pronounced vertebral pain syndrome and improves functional abilities of women with glucocorticoidinduced osteoporosis.
Disclosure of Interest None Declared.